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Abstract
Background: Tissue invasion or tissue infiltration are clinical behaviors of a poor-prognosis subset of meningiomas. We
carried out proteomic analyses of tissue extracts to discover new markers to accurately distinguish between infiltrative and
noninfiltrative meningiomas.
Methodology/Principal Findings: Protein lysates of 64 different tissue samples (including two brain-invasive and 32
infiltrative tumors) were submitted to SELDI-TOF mass spectrometric analysis. Mass profiles were used to build up both
unsupervised and supervised hierarchical clustering. One marker was found at high levels in noninvasive and noninfiltrative
tumors and appeared to be a discriminative marker for clustering infiltrative and/or invasive meningiomas versus
noninvasive meningiomas in two distinct subsets. Sensitivity and specificity were 86.7% and 100%, respectively. This marker
was purified and identified as a multiphosphorylated form of vimentin, a cytoskeletal protein expressed in meningiomas.
Conclusions/Significance: Specific forms of vimentin can be surrogate molecular indicators of the invasive/infiltrative
phenotype in tumors.
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Introduction
Currently, typing and grading a newly diagnosed tumor, the
first steps in appropriate treatment, mainly rely on pathology
analysis and a few biological markers with unambiguous diagnostic
values. There is a need for new diagnosis markers that will also
provide insights into certain specific features of tumors, such as
invasiveness, proliferation, or cytotoxic drug sensitivity. Accurate
markers for early detection of tumors that should thus improve the
efficacy of therapy are also awaited.
Valuable markersfor tumor diagnosis can be discovered using high-
throughput screening of proteins or peptides in biological samples, in
particular using mass-spectrometry techniques. With this strategy,
comparison of protein profiles from sera [1] or from tissue sections
[2,3] has been put forward as a diagnostic approach for tumor
characterization. Although the clinical value of the protein profiles was
questioned [4], individual, valuable markers have been discovered in
sera and identified based on the surface-enhanced laser desorption/
ionization time-of-flight mass spectrometry platform (SELDI-TOF
mass spectrometry), for example [5,6]. SELDI-TOF mass spectrom-
etry is an attractive analytical technology that combines selective
retention of proteins on miniaturized chromatographic surfaces with
mass spectrometric analyses. This facilitates detection and further
purification and identification of biomarkers [7].
The goal of this study was to identify biomarkers that could help to
discriminate different subsets of meningiomas. This work specifically
focused on the study of the infiltrative behavior of this type of tumor.
Meningiomasareslow-growing,extra-axial,andusuallyhistologically
benign tumors. According to the WHO classification, mainly based
on histological features, meningiomas are classified as Grade I
(meningiomas with a low risk of aggressive growth), Grade II (atypical
meningiomas), or Grade III (anaplastic meningiomas) [8]. Interest-
ingly, even in their low-grade status, meningiomas may exhibit
particular phenotypes that are infiltrative to adjacent tissues. One of
thesephenotypes is characterized by meningiomacellinfiltration into
adjacent brain tissue. Typically, this event is specifically called
invasion. Brain invasion is known to be correlated with a high risk of
recurrence and aggressive meningioma behavior [9]. In addition,
other infiltrative events are characterized by individual or combined
infiltrations of meningioma cells into the adjacent bone or the large
‘‘interdural’’ venous cavities of the skull, such as the cavernous sinus
or the venous sinuses. Taken all together, infiltrative phenotypes and
brain invasion can be observed in about 20% of cases, and makes
surgery very difficult. The different infiltrative phenotypes are not
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transformation and it is generally agreed that the histological
appearance of meningiomas often fails to accurately distinguish
between benign meningiomas and potentially infiltrative or invasive
ones, although MRI and CT imaging show evidence of tumoral
infiltration. Molecular biology studies of these tumors may provide a
better appraisal of the clinical and biological potentials of the tumors.
In addition to their prognostic value, biological markers may also
offer opportunities to develop new therapeutic strategies to prevent
tumor progression. With regard to meningiomas, strategies based on
the sex-steroid receptor and some available drugs such as
mifepristone have been proven to be partially effective [10], but the
validation of new therapeutic approaches requires additional study.
We looked for biomarkers directly in tissues by running a multi-
protein detection study using the SELDI-TOF technology. We
found specific discriminative proteomic profiles that help to dis-
tinguish the noninfiltrative and noninvasive meningiomas from the
other infiltrative tumors. Moreover, we purified one phosphorylated
form of vimentin acting as an accurate marker for specific and
sensitive identification of noninvasive meningiomas.
Materials and Methods
Sample Origin
A total of 64 meningioma tissues were collected from surgery
and immediately frozen and stored at 280uC.
Tumor features such as sinus or bone infiltrations were routinely
detected on preoperative MR and CT images. Diagnosis and bone
infiltration were ascertained by pathology examination on paraffin-
embedded tissue samples. Cavernous sinus or venous sinus infil-
trations were confirmed by pathology examination for the presence
of meningioma cells inside adjacent tissues when it was possible to
do so since pathology examinations were most often carried out on
resected samples from outside the sinuses. Brain invasion was
confidently ascertained by pathology examination.
Of the 64 samples, two tumors exhibited brain invasion (tumors
from patients P1 and P24); 32 tumors showed infiltrative beha-
vior (toward one or several vicinal tissues) (tumors from patients
P2–P23 and P25–P34); the other tumors were considered non-
infiltrative and noninvasive (tumors from patients P35–P64).
Tumors were classified using the 2007 WHO classification [8].
Brain-invasive tumors were classified as Grade II, as were tumors
with a high number of mitoses per field as recommended by Perry
et al. [11].
Vimentin, the usual marker for meningioma, was detected
immunohistochemically according to a standard method [12]. A
total of 64 patients’ samples with pathological and clinical features,
as reported in Table 1, were studied and allocated to two groups
(for statistical analysis purposes; see below).
The study was approved by the Biological Resource Center
Ethics Review Board at the Grenoble University Hospital. Written
consent was obtained from each patient or the patient’s family.
SELDI-TOF Mass Spectrometry
Cryostat slices (10 mm thick) were suspended in 300 mL of lysis
buffer (Reporting Lysis Buffer, Promega, Madison, WI, USA)
containing a mix of protease inhibitors (Boehringer/Roche,
Meylan, France), to obtain a final protein concentration close to
2 mg/mL. After 30 min incubation on ice and centrifugation
(10,000 g for 10 min at 4uC), supernatant was diluted in a binding
buffer (100 mM Tris and 0.1% TritonX100 at pH 8.0) to a final
protein concentration of 0.1 mg/mL, and 100 mL of this suspension
was applied to Q10 anion-exchange active binding surfaces of
SELDI ProteinChip Arrays (Bio-Rad, Marnes-La-Coquette,
France). The chips were washed three times with the binding
buffer, then once with the binding buffer without Triton for 5 min,
then once with 2 mM HEPES at pH 7.5. For other analysis
purposes, protein fractions were analyzed on the hydrophilic NP20
ProteinChip Arrays. In this case, active surfaces were washed with
water only. Sinapinic acid was used as the ionization matrix and
ProteinChip Arrays were analyzed both for low- and high-mass
range optimization in a Bio-Rad PCS4000 mass spectrometer.
Protocols for preparing the samples and the arrays for analyses
were followed rigorously since quantitative measurements of
proteins by laser-desorption ionization mass spectrometry depend
on critical parameters such as variability in matrix crystallization
and therefore ionization efficiency. In addition, all spectra were
calibrated using Bio-Rad all-in-one protein calibrants.
Data Analysis
Peaks were automatically detected and normalized to total ion
current intensity in the 4- to 100-kDa range using the Biomarker
Wizard software (Ciphergen, Fremont CA, USA). Peak informa-
tion outputs were used for unsupervised biomarker clustering.
Unsupervised clustering relies on methods that can mine through
data, extracting relevant information, independently of the
information regarding the invasive or noninvasive phenotypes of
the tumors. This was computed by hierarchical clustering using
Cluster software. To investigate the correlation between protein
peaks, visualization was performed with the TreeView Software
(software packages available at http://dnagarden.ims.u-tokyo.ac.
jp/en/doku.php) [13].
For supervised clustering, samples from the two phenotypic
groups (infiltrative/invasive and noninfiltrative/noninvasive ac-
cording to histopathological criteria) were allocated to equivalent
training and testing sets without preset criteria (Table 2). Only the
training set samples were classified for training the Biomarker
Pattern Software 5.0.2 (Ciphergen). Then the sensitivity and
specificity parameters were assessed, with the same software after
analysis of the testing set data.
Purification and Identification of the Protein Marker
The 53-kDa biomarker was purified by chromatography
through a Q HyperD anion exchange column (Pall Biosepra,
Cergy Saint Christophe, France) as follows. A lysis supernatant
obtained as described above was loaded on the top of a 0.5-mL Q
column equilibrated in the binding buffer. The column was then
washed by a solution containing 5% acetonitrile, 0.5% TFA, and
50% isopropanol. Fractions were collected during elution with a
solution made of 16% acetonitrile, 0.1% TFA, and 33%
isopropanol. Aliquots were checked by mass spectrometry analyses
with NP20 ProteinChip Arrays.
Fractions containing the purified biomarker were pooled and
submitted to a 1-D electrophoresis migration under denaturing
conditions in 15% polyacrylamide gels, according to standard
procedures. After Coomassie blue staining, the 53-kDa band was
cut and subjected to GluC endoproteinase or trypsin proteolysis
as described [14]. The peptide mixtures were bound to NP20
ProteinChip Arrays and analyzed using SELDI-TOF mass
spectrometry for fingerprinting analysis and with a MALDI-
TOF/TOF (ABI 4800) mass spectrometer to identify specific
peptides. Trypsin digests were also analyzed by nano-LC-MS/MS
with the nanochromatographic system (Ultimate 3000 – Dionex;
Sunnyvale, CA, USA) directly coupled to an LTQ-Orbitrap
(Thermo Fischer Scientific; Bremen, Germany). Data were
collected and processed automatically using Masslynx 3.5 software.
Protein searches were performed in the SwissProt-TrEMBL decoy
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gram (Matrix Science; http://www.matrixscience.com).
Fractions containing the purified biomarker were vacuum dried.
The sample was then resuspended in Tris-Cl 0.1 M, MgCl2
10 mM, pH 8.8, and the pH of the suspension was controlled.
Then phosphatase treatment was performed for 1 h at 30uC with
calf alkaline phosphatase. Two different types of phosphatase were
used: soluble (Roche) or agarose-crosslinked (Sigma; St Louis,
MO, USA) calf intestine alkaline phosphatases.
Both the purified protein and the phosphatase-treated sample
were analyzed by SELDI-TOF mass spectrometry using NP20
ProteinChip Arrays or Q10 anion-exchange ProteinChip Arrays
as described above. Controls that were run in the absence of
phosphatase established that the observed mass shifts were not due
to any protease activity.
Results
Intratumoral Protein Content Analysis by SELDI-TOF Mass
Spectrometry
Solubilized protein extracts were prepared from the tissue
samples of 64 meningiomas including 32 infiltrative, two brain-
invasive, and 30 noninfiltrative tumors (Tables 1 and 2). Protein
patterns were generated by SELDI-TOF mass spectrometry with
the Q10 anion-exchange ProteinChip Arrays. Mass spectra
detected 69 different statistically significant peaks (in the 4- to
100-kDa range) that were putative biomarkers distinguishing the
noninfiltrative meningiomas from the others.
We performed a hierarchical clustering analysis based on the
whole set of protein peaks detected by the Biomarker Wizard
software using the Cluster and TreeView programs. This un-
supervised clustering segregated most of the infiltrative/invasive
and noninfiltrative tumors into two distinct clusters (Figure 1). The
accuracy of this classification was about 82% (four noninfiltrative
and eight infiltrative/invasive samples were misclassified to the two
opposite groups). The result of this clustering suggested that an
infiltrative/invasive versus noninfiltrative phenotypic segregation
of the tumors could be possible based on the SELDI-TOF mass
spectrometry patterns of the tissue extracts.
One Marker Adequately Differentiates Infiltrative/Invasive
and Noninfiltrative Tumors
We then attempted to recognize the smallest set of markers with
the best discriminative ability to appropriately classify the samples.
Briefly, a training set of samples composed of 17 infiltrative/
invasive and 15 noninfiltrative tumors was designed (Table 2) and
a supervised clustering was done using the Biomarker Pattern
Software. This analysis revealed that a single, unique molecular
marker is adequate for discrimination of the noninfiltrative versus
infiltrative/invasive tumors. After clustering the training set, this
information was used for predictive classification of the samples in
the testing set (Table 2). Sensitivity and specificity values of 86.7%
and 100%, respectively, were obtained for this marker. This
emphasized that noninfiltrative tumors behave as a homogeneous
group of tumors that can be easily distinguished from infiltrative/
invasive tumors on the basis of the detection of this newly
discovered marker. In addition, tumors with infiltrative or invasive
phenotypes shared similar profiles with a very low detection level
of the marker, independently of their individual infiltrative features
(i.e., individual or combined infiltrations/invasions of sinuses,
bone, or brain). This marker was characterized by a 53-kDa
molecular mass. A typical comparison of the mass spectra
recorded in the range between 20 and 60 kDa for two tumors
Table 2. Features of the sample groups.
Training set Testing set Total
Number of patients 32 32 64
Age: mean in years (range) 58.4 (32–79) 57.2 (35–76) (32–79)
Men/women 6/26 7/25 13/51
Total number of noninfiltrative tumors 15 15 30
Total number of tumors with infiltrative
or invasive features (tumors may have
several infiltrative features)
17 17 34
Cavernous sinus or sagittal sinus
infiltration
12 11 23
Bone infiltration 13 10 23
Cortex invasion 1 1 2
doi:10.1371/journal.pone.0009238.t002
Figure 1. Unsupervised hierarchical clustering of the tumors.
Two-dimensional hierarchical clustering of 64 tumors (32 infiltrative,
two invasive, and 30 noninvasive tumors) was performed with 69
molecular mass peaks after SELDI-TOF mass spectra processing with the
Biomarker Wizard software (Ciphergen). Candidate markers and patient
samples were clustered using complete linkage clustering methods
from Eisen’s cluster software. Clustered trees are displayed using Eisen’s
Treeview software. Red squares denote high marker concentration in
comparison to average; green squares denote low concentration in
comparison to average. The numbers of infiltrative or invasive samples
and of noninfiltrative or noninvasive samples in the two clusters are
indicated.
doi:10.1371/journal.pone.0009238.g001
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shown in Figure 2.
Under the experimental conditions used herein, the intensity of
the 53-kDa molecular mass was found to average at a value of 0.35
arbitrary units (median, 0.33) for the extracts of the infiltrative/
invasive tumors, contrasting with the value of 3.94 arbitrary units
(median, 2.90) measured for the samples from the noninfiltrative
tumors with a highly discriminative significance level (p-value
,0.0001) (Figure 3).
Identification of the 53-kDa Biomarker
In the first step, the optimal conditions for binding the marker
to anion-exchange active surfaces and for elution after binding
were determined on a miniaturized scale. This was done by
incubating solubilized tissue extracts in the presence of various
buffers on Q10 ProteinChip Arrays and assaying by mass
spectrometry the desorption of the bound biomarker after
incubation with several eluting solutions. Large-scale purification
of the biomarker was then carried out on Q HyperD columns (the
chemical properties of the column resin are identical to those of
the Q10 active surfaces) using the binding and eluting solutions
specified previously. Purification was completed by 1-D polyacryl-
amide gel electrophoresis under denaturing conditions (Figure 4)
and the 53-kDa stained band was excised and submitted to
digestion by proteolytic enzymes.
After this treatment, peptides released from the piece of gel were
analyzed by SELDI-TOF mass spectrometry to generate a peptide
mass fingerprint and by nanoLC-MS/MS to obtain additional
information regarding the amino-acid sequence of the peptides.
Both approaches demonstrated that the purified 53-kDa biomark-
er was vimentin. A peptide profile obtained after GluC
endoproteinase digestion of the 53-kDa biomarker (cleavage at
the carboxyl groups of glutamic acid residues) is shown in
Figure 5A. On the basis of the molecular masses, twelve peaks in
this profile were found to match with GluC endoproteinase
fragments of vimentin (Figure 5B and 5C). In addition, after
trypsin treatment of the purified biomarker (cleavage at the
carboxyl groups of arginine and lysine amino acids) and peptide
analysis using nanoLC-MS/MS, data were analyzed against the
Swiss-prot TrEMBL decoy database. The intensities and conti-
nuity of matched fragment ions in b, y series led to unambiguous
Figure 2. Protein profiling by SELDI-TOF mass spectrometry on Q10 anion-exchange ProteinChip Arrays. Two representative sample
extracts were analyzed, one from an infiltrative tumor (A and C) and one from a noninfiltrative tumor (B and D). (A and B) Mass spectra traces in the
20- to 60-kDa range. (C and D) gel views of the A and B spectra, respectively. Arrow in panel B shows the 53-kDa marker in the noninfiltrative tumor
extract.
doi:10.1371/journal.pone.0009238.g002
Figure 3. Quantitative assessment of the 53-kDa marker in the
clinical samples. Tumor extracts were analyzed using SELDI-TOF on
Q10 anion-exchange ProteinChip Arrays, as shown in Figure 2. Signal
intensity at the 53-kDa mass level were measured and calculated
parameters plotted for (A) infiltrative/invasive tumor samples, (B)
noninfiltrative tumor samples. Medians, 25
th and 75
th percentiles are
marked with line segments across the boxes and the lowest and highest
signal values with bars.
doi:10.1371/journal.pone.0009238.g003
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through Mascot search engines. The cumulated length of all the
trypsin peptides identified encompassed 91% of the total length of
vimentin (Figure 5C).
We then immunodetected vimentin in meningioma tumor slices
with a vimentin-directed monoclonal antibody. No significant
quantitative correlation was observed for the different tissue
samples, between antigen reactions and their infiltrative/invasive
or noninfiltrative status (not shown). Assessment of the total
concentration of vimentin by SELDI-TOF analyses on NP20
ProteinChip Arrays to allow detection of both natural and
modified forms of vimentin also failed to detect any significantly
different concentration in the samples. Moreover, we found no
significant variation of the vimentin-transcript levels in the various
samples when assayed by cDNA hybridization to oligonucleotide-
microarrays (not shown). This indicated that assay of the vimentin
transcript in these tumors cannot be used to predict invasiveness.
All these observations were taken as indications that in
noninfiltrative tissues, the vimentin detected by adsorption to the
Q10 anion-exchange ProteinChip Arrays was in fact a non-native
form of vimentin.
We were intrigued by the tight binding of vimentin on the Q10
anion-exchange ProteinChip Arrays. The protein was not eluted
even by a pH 3.0 buffer, even though vimentin has a computed
isoelectric point of 5. It was hypothesized that the presence of
phospho-esterified amino acids in the protein would explain this
striking anionic feature. This was ascertained by the fact that after
alkaline phosphatase treatment, the form of vimentin, purified
from noninfiltrative tumors, was no longer able to bind to the Q10
anion-exchange ProteinChip Arrays (Figure 6). In this dephos-
phorylated state, vimentin was still able to bind to the hydrophilic
Figure 4. Purification of the 53-kDa marker. Lysates from
noninfiltrative tissues were submitted to the purification method
reported in Materials and Methods. Quality control was run on a 12%
polyacrylamide gel under denaturing conditions and the 53-kDa band
was cut and further subjected to analysis for identification. Lane 1: mass
ladder; lanes 2 and 3: purified 53-kDa marker (0.5 mg and 20 mg,
respectively); lane 4: meningioma lysate.
doi:10.1371/journal.pone.0009238.g004
Figure 5. The 53-kDa marker identified as vimentin. After purification by chromatography and electrophoresis, the 53-kDa marker was cleaved
by proteases. (A) peptide fingerprint after GluC endoproteinase digestion obtained by SELDI-TOF analysis on NP20 ProteinChip Arrays. Peptides with
measured molecular masses matching those of the computed GluC endoproteinase proteolytic peptides of vimentin are indicated with an asterisk.
(B) GluC endoproteinase peptides of vimentin identified by SELDI-TOF are listed according to their masses. (C) Mapping of the peptides identified by
either peptide mass fingerprinting or nanoLC-MS/MS to the vimentin sequence. Sequences highlighted in grey correspond to GluC endoproteinase
peptides identified in B. Underlined sequences correspond to 60 trypsin peptides identified by nanoLC-MS/MS. Phosphorylated peptides (37-50
amino acid and 70-78 amino acid peptides) are underlined with dots.
doi:10.1371/journal.pone.0009238.g005
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lowered by about 300 Da. This mass shift suggested that nearly
three phospho-groups per molecule of modified vimentin were
removed during the phosphatase treatment. NanoLC-MS/MS
data analysis indicated that two vimentin tryptic peptides exhibited
a mass supplement corresponding to the addition of one phosphate
group (peptide from amino acid 37 to 50, which contains four
serine, two threonine, and one tyrosine residue, and peptide from
amino acid 70 to 78, which contains two serine residues).
Commercially available polyclonal antibodies directed against
seven different phosphorylated-vimentin peptides were used in
Western blots to identify specific vimentin phosphosites in lysates
from noninfiltrative or infiltrative meningiomas. Phosphorylated
epitopes were detected in the meningioma samples by only two of
these antibodies. However, the intensities of the immunoreactiv-
ities were found to be identical in both types of lysates. This result
suggests that at least serine residues 51 and 72 (see vimentin
sequence in Figure 5) are not specifically phosphorylated in the
noninfiltrative meningiomas. Additional investigations are there-
fore required to identify the specific phosphorylated amino acid
residues in the vimentin form that is present in greater amount in
noninfiltrative meningiomas.
Finally, this study demonstrated that in meningiomas, an
increase of vimentin concentration is probably not a molecular
event indicative of invasiveness per se but more accurately the
presence of the protein in a multiphosphorylated form is an
indicator for noninvasiveness.
Discussion
Phosphorylated Vimentin as a Marker for Differentiation
between Infiltrative/Invasive and Noninfiltrative
Meningiomas
The proteomic patterns of meningiomas were analyzed with the
aim of discovering new biomarkers or molecular events that are
indicative of their infiltrative or invasive phenotypes. These
phenotypes were defined as the feature of meningiomas that
infiltrate adjacent tissues such as bone or venous complex sinuses
(cavernous sinus or superior longitudinal or lateral/sigmoid
sinuses) or invade brain tissue. Meningiomas allowed a molecular
characterization of proteomic markers related to infiltration/
invasion, in the clinical context of low-grade, low-proliferation
benign tumors. This proteomic study was conducted using a
SELDI-TOF mass spectrometry approach on solubilized tissue
extracts. We discovered one biomarker that has a clear ability to
discriminate between infiltrative/invasive and noninfiltrative
tumors. This marker was identified as a multiphosphorylated
form of vimentin. This post-translational modified vimentin is
found in noninfiltrative tumors at easily-detectable levels.
Vimentin in Physiological and Pathological Contexts
Vimentin is a 466-amino-acid-long protein with a 53,652-Da
molecular mass (Uniprot, http://www.uniprot.org, P08670). It is
encoded by a single-copy gene located on chromosome 10q13.
Vimentin is naturally expressed in nonepithelial cells and in
mesenchymatous cells. In the central nervous system, vimentin is
absent from oligodendrocytes, mature astrocytes, and neurones,
but it is expressed in the Schwann cells and ependyma cells. Under
certain specific physiological or pathological conditions, cellular
levels of vimentin might be up- or downregulated. Vimentin was
found to be detectable in astrocytomas and glioblastomas (grade
IV astrocytomas), meningiomas, and ependymomas but not in
oligodendrogliomas and medulloblastomas [15,16].
Numerous data in the literature have already reported that some
cytoskeleton constituents are expressed in epithelial cells with
concomitant acquisition of new morphological and migratory
phenotypes, a phenomenon called epithelial-mesenchymal transi-
tion. More specifically, overexpression of vimentin, one polypeptide
of the type III intermediate filaments, is often believed to be
correlated with the invasiveness or increased metastatic potential of
many tumors [17–20]. Consequently, detection of vimentin in
tumors has been considered a biological marker of poor prognosis
[21]. However, several other authors disagreed with this statement
[22–24]. Additionally, overexpression of vimentin induced by stable
transfection of expression constructs in tumoral cells was unable to
enhance invasiveness in poorly invasive prostatic tumor [25] or was
shown, on the contrary, to decrease hepatocarcinoma proliferation
[26]. Thus, understanding the correlation between overexpression
of vimentin and tumor invasiveness still calls for additional studies.
Vimentin is a target for several post-translational modifications
and some of these modifications may be linked with diverse
pathologies. For example, upregulation of an N-terminus truncat-
ed vimentin was observed in Ha-ras transfected tumorigenic rat
liver cells [27]. In addition, an unidentified specific vimentin
isoform was found to elicit antibody production in pancreatic
cancer [28]. In rheumatoid arthritis, modified citrullinated
vimentin isoforms are generated and act as autoantigens [29,30].
Antibodies against citrullinated proteins are assumed to play a role
in the pathogenesis of arthritis [31]. Finally, O-linked beta-N-
acetylglucosamine modification of vimentin can be observed
during cell cycle progression [32].
Figure 6. The 53-kDa marker is a phosphorylated form of
vimentin. Purified 53-kDa marker from noninfiltrative tissue extracts
was treated by alkaline phosphatase and samples were analyzed using
SELDI-TOF MS. Analyses were performed on Q10 anion-exchange
ProteinChip Arrays (A and B) or hydrophilic NP20 ProteinChip Arrays (C
and D). (A and C) Controls with untreated purified 53-kDa marker. (B
and D) phosphatase-treated marker.
doi:10.1371/journal.pone.0009238.g006
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Close to 40 different phosphorylated sites have been experimen-
tally identified (Uniprot, http://www.uniprot.org, P08670 and
references therein) [33–38]. Roughly 30 serine residues are targets
for phosphorylation and 21 of them are located in the first 100
amino acids at the N terminus of vimentin. Five threonines and
four tyrosines were also identified as phosphosites (Uniprot,
http://www.uniprot.org, P08670 and references therein). Phos-
phorylation has been reported to be catalyzed by numerous
kinases such as cAMP-dependent protein kinase (PKA), protein
kinase C, Ca
++/calmodulin-dependent protein kinase-II, cdc2
kinase, PKN, Rho-kinase, mitogen-activated protein kinase-
activated protein kinase-2 (MAPKAP kinase-2), and p21-activated
kinase (PAK) [33–40]. It is also worth mentioning that vimentin is
one of the usual protein markers detected by immunohistochem-
istry for the definite diagnosis of meningiomas whatever their
invasive or noninvasive phenotype is. Our present data clearly
illustrate that, in meningiomas that infiltrate bone or sinuses, the
infiltrative behavior of these tumors correlates better with the level
of phosphorylated vimentin than with the global expression level
of this protein. With a structural function of vimentin in the
cytoskeletal scaffolding, it can be assumed that vimentin plays a
key role in the process of tumor cell migration or motility. It is
interesting to note that in breast tumor cells, vimentin filament
assembly plays a direct role in the stability of a type of cellular
protrusions, called tubulin microtentacles, that are involved in
tumor invasiveness [41]. A decrease in microtentacle frequency
was observed in noninvasive, non-vimentin-expressing breast
carcinomas or in cells expressing a dominant-negative vimentin
mutant that promotes vimentin filament disruption or after cell
treatment with inhibitors of PP1/PP2A phosphatases. This last
observation is in line with the fact that vimentin phosphorylation is
known to play a role in disassembly of the intermediate filaments
during mitosis [32,42]. Accordingly, it can be hypothesized that
excessive phosphorylation of vimentin, as a process leading to
vimentin filament disassembly, may underlie important steps in
migratory control of meningioma cells.
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